Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Linjie Luo & Khandan Keyomarsi. (2022) PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion on Investigational Drugs 31:6, pages 607-631.
Read now
Read now
Xuan Jiang, Weihua Li, Xiaoying Li, Huimin Bai & Zhenyu Zhang. (2019) Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Management and Research 11, pages 4371-4390.
Read now
Read now
Khalid El Bairi, Mariam Amrani, Abdul Hafeez Kandhro & Said Afqir. (2017) Prediction of therapy response in ovarian cancer: Where are we now?. Critical Reviews in Clinical Laboratory Sciences 54:4, pages 233-266.
Read now
Read now
Josee-Lyne Ethier, Stephanie Lheureux & Amit Oza. (2016) The role of cediranib in ovarian cancer: current status and further investigation. Expert Opinion on Orphan Drugs 4:8, pages 855-865.
Read now
Read now
Articles from other publishers (30)
Deyu Li, Zhangzhou Huang, Jiangming Zhong, Li Lin, Guifeng Zhang, Wu Zhuang & Zhenhua Liu. (2023) Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study). BMC Cancer 23:1.
Crossref
Crossref
Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu & Xiaoguang Chen. (2022) A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Frontiers in Pharmacology 13.
Crossref
Crossref
Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Andrew N. J. Tutt & Christopher J. Lord. (2022) Opinion: PARP inhibitors in cancer—what do we still need to know?. Open Biology 12:7.
Crossref
Crossref
Mohammad Malekan & Mohammad Ali Ebrahimzadeh. (2022) Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in
Breast Cancer Treatment: Current Status in Preclinical and Clinical
Studies and Future Directions. Current Topics in Medicinal Chemistry 22:11, pages 891-920.
Crossref
Crossref
Binbin Cheng, Wei Pan, Yi Xing, Yao Xiao, Jianjun Chen & Zheng Xu. (2022) Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. European Journal of Medicinal Chemistry 230, pages 114109.
Crossref
Crossref
Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, Alessia Anastasia, Massimo Russo, Giovanna Damia, Federica Guffanti, Francesca Guana, Paola Ostano, Lucia Minoli, Maureen M. Hattersley, Stephanie Arnold, Antonio Ramos-Montoya, Stuart C. Williamson, Alessandro Galbiati, Jelena Urosevic, Elisabetta Leo, Ugo Cavallaro, Carmen Ghilardi, Simon T. Barry, Maria Rosa Bani & Raffaella Giavazzi. (2021) VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Hongyan Cheng, Ruiqiong Ma, Shang Wang, Yu Wang, Yingchun Li, Zhijian Tang, Sha Dou, Yuanfen Wang, Honglan Zhu, Xue Ye, Tianyu Zhang, Yonghua Zhang, Shufen Li, Yonghong Zhao, Yi Li, Heng Cui & Xiaohong Chang. (2021) Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. Frontiers in Immunology 12.
Crossref
Crossref
Angeles Alvarez Secord, David M. O'Malley, Anil K. Sood, Shannon N. Westin & Joyce F. Liu. (2021) Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecologic Oncology 162:2, pages 482-495.
Crossref
Crossref
Komal Thapa, Heena Khan, Uma Sharma, Amarjot Kaur Grewal & Thakur Gurjeet Singh. (2021) Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases. Life Sciences 267, pages 118975.
Crossref
Crossref
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin & Steve Jia. (2020) Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. Anti-Cancer Drugs 31:2, pages 101-109.
Crossref
Crossref
Stefan Poschner, Judith Wackerlig, Dan Cacsire Castillo-Tong, Andrea Wolf, Isabel von der Decken, Tea Lanišnik Rižner, Renata Pavlič, Anastasia Meshcheryakova, Diana Mechtcheriakova, Monika Fritzer-Szekeres, Theresia Thalhammer & Walter Jäger. (2020) Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells. Cancers 12:2, pages 279.
Crossref
Crossref
Yoonjung Kim, Chi-Heum Cho, Jung-Sook Ha, Do-Hoon Kim, Sun Young Kwon, Seoung Chul Oh & Kyung-A Lee. (2020)
An optimized
BRCA1/2
next-generation sequencing for different clinical sample types
. Journal of Gynecologic Oncology 31:1.
Crossref
Crossref
Hehua Xiong, Yanli Gao, Qi Yang, Qidong Tang & Pengwu Zheng. (2019) Synthesis of Ethyl 4-(4-Nitrophenoxy) Picolinate. IOP Conference Series: Materials Science and Engineering 677:2, pages 022072.
Crossref
Crossref
Ning Zhu, Shanshan Weng, Juan Wang, Jiaqi Chen, Linzhen Yu, Xuefeng Fang & Ying Yuan. (2019) Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of Cancer Research and Clinical Oncology 145:12, pages 3021-3036.
Crossref
Crossref
Jingyan Yi, Chongya Liu, Zhiwei Tao, Min Wang, Yaxun Jia, Xiaolin Sang, Lanlin Shen, Yijue Xue, Kui Jiang, Fuwen Luo, Pixu Liu & Hailing Cheng. (2019) MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine 43, pages 225-237.
Crossref
Crossref
Stephanie Lheureux, Charlie Gourley, Ignace Vergote & Amit M Oza. (2019) Epithelial ovarian cancer. The Lancet 393:10177, pages 1240-1253.
Crossref
Crossref
Abdul Khalid Siraj, Poyil Pratheeshkumar, Sandeep Kumar Parvathareddy, Sasidharan Padmaja Divya, Fouad Al-Dayel, Asma Tulbah, Dahish Ajarim & Khawla S. Al-Kuraya. (2018) Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment. Oncotarget 9:99, pages 37319-37332.
Crossref
Crossref
Gauthaman Kalamegam, Khalid Hussein Wali Sait, Farid Ahmed, Roaa Kadam, Peter Natesan Pushparaj, Nisreen Anfinan, Mahmood Rasool, Mohammad Sarwar Jamal, Muhammed Abu-Elmagd & Mohammed Al-Qahtani. (2018) Human Wharton's Jelly Stem Cell (hWJSC) Extracts Inhibit Ovarian Cancer Cell Lines OVCAR3 and SKOV3 in vitro by Inducing Cell Cycle Arrest and Apoptosis. Frontiers in Oncology 8.
Crossref
Crossref
Joyce F. LiuJung-min LeeEllie StrockRuth PhillipsKarine MariBill KilliamMatthew BonamTsveta MilenkovaElise C. KohnS. Percy Ivy. (2018) Technology Applications: Use of Digital Health Technology to Enable Drug Development. JCO Clinical Cancer Informatics:2, pages 1-12.
Crossref
Crossref
Z. Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, Jake Moscarelli, Amy Xiong, Yasmin Korayem, Pamela H. Huang, Smith Giri, Patricia LoRusso & Elena S. Ratner. (2018) Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLOS ONE 13:11, pages e0207399.
Crossref
Crossref
Janel Kydd, Rahul Jadia & Prakash Rai. (2018) Co-Administered Polymeric Nano-Antidotes for Improved Photo-Triggered Response in Glioblastoma. Pharmaceutics 10:4, pages 226.
Crossref
Crossref
Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli & Elvira Pelosi. (2018) Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines 5:1, pages 16.
Crossref
Crossref
Aurélie Auguste & Alexandra Leary. (2017) Anomalies de la réparation de l’ADN et cancers gynécologiques. Bulletin du Cancer 104:11, pages 971-980.
Crossref
Crossref
Caroline Lum & Christopher B. Steer. (2017) Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. Drugs & Aging 34:11, pages 821-831.
Crossref
Crossref
Jung-Min LeeAshley Cimino-MathewsCody J. PeerAlexandra ZimmerStanley LipkowitzChristina M. AnnunziataLiang CaoMaria I. HarrellElizabeth M. SwisherNicole HoustonDana-Adriana BotesteanuJanis M. TaubeElizabeth ThompsonAleksandra OgurtsovaHaiying XuJeffers NguyenTony W. HoWilliam D. FiggElise C. Kohn. (2017) Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology 35:19, pages 2193-2202.
Crossref
Crossref
Laura M. Tanenbaum, Aikaterini Mantzavinou, Kriti S. Subramanyam, Marcela G. del Carmen & Michael J. Cima. (2017) Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter. Gynecologic Oncology 146:1, pages 161-169.
Crossref
Crossref
Elise C. KohnS. Percy Ivy. (2017) Whence High-Grade Serous Ovarian Cancer. American Society of Clinical Oncology Educational Book:37, pages 443-448.
Crossref
Crossref
Christopher J. Lord & Alan Ashworth. (2017) PARP inhibitors: Synthetic lethality in the clinic. Science 355:6330, pages 1152-1158.
Crossref
Crossref
Alexandra Leary, Aurelie Auguste & Soizick Mesnage. (2016) DNA damage response as a therapeutic target in gynecological cancers. Current Opinion in Oncology 28:5, pages 404-411.
Crossref
Crossref
S.M. Crafton, K. Bixel & J.L. Hays. (2016) PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials. Gynecologic Oncology 142:3, pages 588-596.
Crossref
Crossref